Herpes Zoster Therapeutics Market Size to Grow by USD 4.51 Billion | By Product (vaccination and drug therapy) and Geography | Global Opportunity Analysis and Industry Forecast, 2022-2026 – Press Release
[ad_1]
NEW YORK, April 8, 2022 /PRNewswire/ — The Herpes Zoster Therapeutics Market value is set to grow by USD 4.51 billion, progressing at a CAGR of 14.67% from 2021 to 2026, as per the latest report by Technavio.
The market is segmented by Product (vaccination and drug therapy) and Geography (North America, Europe, Asia, and ROW). Moreover, the increased incidence of herpes zoster is notably driving the herpes zoster therapeutics market growth, although factors such as the weak pipeline for herpes zoster therapeutics may impede the market growth.
Request a free sample report to know exact growth variance and the Y-O-Y growth rate
|
Herpes Zoster Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 14.67% |
|
Market growth 2022-2026 |
$ 4.51 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
10.40 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 41% |
|
Key consumer countries |
US, Germany, China, Canada, and UK |
|
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
|
Companies profiled |
Abbott Laboratories, Bausch Health Companies Inc., Zydus Lifesciences Ltd., Cipla Ltd., Eli Lilly and Co., Emcure Pharmaceuticals Ltd., GlaxoSmithKline Plc, Maruho Co. Ltd., Merck and Co. Inc., and Novartis AG |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for the forecast period, |
|
Customization preview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Herpes Zoster Therapeutics Market 2022-2026: Segmentation
- Product
- Vaccination
- Drug Therapy
The herpes zoster therapeutics market share growth by the vaccination segment will be significant during the forecast period. Vaccines are among the most important biologic therapies that help in the prevention of various disease outbreaks. The importance of vaccines comes from the fact that they are able to provide active immunization, wherein dead or live microbial antigens are administered to individuals before they are naturally infected by the antigen. After immunization, if the person gets infected by that antigen, there will be sufficient antibodies present in the body, which will rapidly eliminate that antigen. Such effective application of vaccines will positively impact the segment growth during the forecast period.
Request for a FREE sample to gain further insights on the market contribution of various segments
- Geography
- North America
- Europe
- Asia
- ROW
The 41% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for herpes zoster therapeutics market in North America. Market growth in this region will be faster than the growth of the market in ROW.
The sales of drugs and vaccines used in the treatment/prophylaxis of herpes zoster will facilitate the herpes zoster therapeutics market growth in North America …
Full story available on Benzinga.com
[ad_2]
Source link
